Patent Approval for GPCR Biosensors

French biopharma Domain Therapeutics, developers of drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, has been granted a patent in the US and in Europe, covering a novel family of biosensors that monitor biomolecule localisation and trafficking in cells.

The patent, was initially filed by Prof. Michel Bouvier and his team and is part of the technology licensed to Domain Therapeutics by the Universities of Montreal and McGill, Canada. The biosensors are designed to profile G Proteins, including G12 and G13, Beta-arrestins, second messengers and receptor trafficking.

“This granted patent illustrates our strategy to stay at the forefront of innovation in technologies for challenging GPCRs. It will help the company address unmet medical needs with drugs acting through brand new mechanisms of action,” said Pascal Neuville, CEO, Domain Therapeutics. “In collaboration with Prof. Michel Bouvier, we have already taken advantage of this unique technology to launch a chaperone program targeting a mutated GPCR with impaired trafficking.”